Fedratinib treatment is effective in patients with myelofibrosis (MF) who discontinued ruxolitinib due to treatment failure, according to data from a real-world study published in the scientific journal Future Oncology.
The findings of this study offer a new option for patients with MF whose disease does not respond to ruxolitinib treatment.
To assess the real-world treatment patterns with fedratinib as well as clinical outcomes in patients with primary or secondary MF after ruxolitinib discontinuation, a team of researchers conducted a retrospective, noninterventional medical record review of 196 patients with MF in Germany, Canada, and the United Kingdom.
Data about the patients was provided by 70 physicians of whom 78.6% were primarily hematologists or oncologists.
Of these 196 patients, the majority (76.5%) had primary MF and started treatment with fedratinib at a mean age of 67.7 .
The median duration of treatment with fedratinib was 11.5 months and the median follow-up period was 13.8 months. Almost half (49.5%) of patients started fedratinib at the dose indicated on the label, i.e. 400 mg per day.
Six months after the start of treatment with fedratinib, 77.7% of patients had symptom response and 66.8% had spleen response.